Given that the extent of neurological damage and dysfunction is likely greater for AD patients than cognitively normal patients deemed at risk of AD, AD patients may require more invasive routes for delivering IGF2 to the CNS in order to receive a beneficial effect. This evidence concerns the gene IGF2 and Alzheimer disease.